Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: coronary restenosis therapy - SIDR

Drug Profile

Research programme: coronary restenosis therapy - SIDR

Alternative Names: Coronary restenosis therapy research programme - SIDR; Coronary restenosis therapy research programme - Strathclyde Institute for Drug Research; Research programme: coronary restenosis therapy - Strathclyde Institute for Drug Research; Research programme: restenosis therapy - Strathclyde Institute for Drug Research; Restenosis therapy research programme - SIDR; Restenosis therapy research programme - Strathclyde Institute for Drug Research

Latest Information Update: 05 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Strathclyde Institute for Drug Research
  • Class
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronary artery restenosis

Most Recent Events

  • 05 Feb 2008 No development reported - Preclinical for Coronary artery restenosis in United Kingdom (unspecified route)
  • 13 Mar 2000 This programme is available for licensing (http://www.sidr.org)
  • 20 Jul 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top